What is Kiora Pharmaceuticals?
Kiora Pharmaceuticals operates at the intersection of advanced molecular biology and ophthalmology. The company is dedicated to the research and development of novel treatments for retinal degeneration and inflammatory eye conditions. By targeting the underlying biological pathways that contribute to vision loss, Kiora distinguishes itself within the competitive healthcare sector. Its business model relies on rigorous clinical trial execution and strategic partnerships to navigate the complex regulatory landscape of drug development, ensuring that its investigational therapies move efficiently toward commercialization. The firm's focus remains on conditions where current therapeutic options are insufficient, positioning it as a key player in the future of vision-restorative medicine.
How much funding has Kiora Pharmaceuticals raised?
Kiora Pharmaceuticals has raised a total of $11.2M across 5 funding rounds:
Debt
$968K
Debt
$994K
Stock Offering
$4.1M
Debt
$150K
Stock/Share Issuance
$5M
Debt (2013): $968K, investors not publicly disclosed
Debt (2014): $994K, investors not publicly disclosed
Stock Issuance/Offering (2015): $4.1M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Stock/Share Issuance (2026): $5M, investors not publicly disclosed
Key Investors in Kiora Pharmaceuticals
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support late-stage clinical development.
PPP
Public-Private Partnership
Undisclosed Investor
A private investment group focused on long-term growth within the biotechnology and life sciences sector.
What's next for Kiora Pharmaceuticals?
With the recent influx of capital, Kiora Pharmaceuticals is well-positioned to advance its clinical programs through critical development milestones. The strategic allocation of these funds will likely prioritize the expansion of clinical trial capacity and the refinement of its small-molecule platform. As the company moves forward, stakeholders will be monitoring the progression of its lead candidates through regulatory phases. The firm's ability to maintain its momentum in the ophthalmic space will depend on its success in demonstrating efficacy and safety in its ongoing trials, ultimately aiming to provide transformative solutions for patients suffering from degenerative eye diseases.
See full Kiora Pharmaceuticals company page
